10 The vast majority of cancers have mutation or gene amplification in a targetable signaling pathway (receptor tyrosine kinases such as MET or EGFR, JAK/STAT, GTPase (RHO/RAS/RAF), PIK3CA/MTOR/PTEN, CTNNB1). This evidence concerns the gene RHO and cancer.